<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p191" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_191{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_191{left:306px;bottom:30px;}
#t3_191{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_191{left:346px;bottom:30px;}
#t5_191{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_191{left:517px;bottom:30px;}
#t7_191{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_191{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_191{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_191{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_191{left:35px;bottom:777px;letter-spacing:0.08px;word-spacing:-0.6px;}
#tc_191{left:35px;bottom:754px;letter-spacing:0.04px;word-spacing:0.39px;}
#td_191{left:347px;bottom:761px;}
#te_191{left:35px;bottom:713px;letter-spacing:0.04px;word-spacing:0.15px;}
#tf_191{left:35px;bottom:690px;letter-spacing:0.28px;word-spacing:-1.32px;}
#tg_191{left:121px;bottom:698px;letter-spacing:-0.01px;}
#th_191{left:143px;bottom:690px;letter-spacing:0.01px;word-spacing:-1.06px;}
#ti_191{left:35px;bottom:667px;letter-spacing:0.05px;}
#tj_191{left:75px;bottom:675px;letter-spacing:0.12px;}
#tk_191{left:142px;bottom:667px;letter-spacing:-0.03px;word-spacing:0.22px;}
#tl_191{left:35px;bottom:645px;letter-spacing:0.12px;word-spacing:-0.29px;}
#tm_191{left:35px;bottom:622px;letter-spacing:0.16px;word-spacing:0.02px;}
#tn_191{left:35px;bottom:599px;letter-spacing:0.19px;}
#to_191{left:35px;bottom:575px;letter-spacing:0.13px;}
#tp_191{left:103px;bottom:583px;letter-spacing:0.13px;}
#tq_191{left:214px;bottom:575px;letter-spacing:0.09px;word-spacing:0.1px;}
#tr_191{left:35px;bottom:552px;letter-spacing:0.18px;}
#ts_191{left:35px;bottom:529px;letter-spacing:0.05px;word-spacing:-1.09px;}
#tt_191{left:207px;bottom:536px;letter-spacing:-0.01px;}
#tu_191{left:229px;bottom:529px;letter-spacing:0.08px;word-spacing:0.11px;}
#tv_191{left:35px;bottom:506px;letter-spacing:0.1px;word-spacing:0.08px;}
#tw_191{left:35px;bottom:482px;letter-spacing:0.14px;word-spacing:0.06px;}
#tx_191{left:339px;bottom:482px;}
#ty_191{left:354px;bottom:482px;letter-spacing:0.01px;word-spacing:0.18px;}
#tz_191{left:35px;bottom:459px;letter-spacing:0.12px;word-spacing:0.07px;}
#t10_191{left:35px;bottom:436px;letter-spacing:0.08px;word-spacing:0.11px;}
#t11_191{left:35px;bottom:413px;letter-spacing:0.12px;word-spacing:0.06px;}
#t12_191{left:158px;bottom:413px;}
#t13_191{left:174px;bottom:413px;letter-spacing:0.22px;word-spacing:-0.04px;}
#t14_191{left:224px;bottom:420px;letter-spacing:-0.01px;}
#t15_191{left:246px;bottom:413px;letter-spacing:0.1px;word-spacing:0.09px;}
#t16_191{left:35px;bottom:390px;letter-spacing:0.13px;word-spacing:0.06px;}
#t17_191{left:35px;bottom:366px;letter-spacing:-0.07px;}
#t18_191{left:176px;bottom:374px;letter-spacing:-0.01px;}
#t19_191{left:35px;bottom:326px;letter-spacing:0.09px;word-spacing:0.45px;}
#t1a_191{left:35px;bottom:303px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1b_191{left:378px;bottom:310px;}
#t1c_191{left:423px;bottom:303px;letter-spacing:-0.11px;word-spacing:1.51px;}
#t1d_191{left:35px;bottom:280px;letter-spacing:0.12px;word-spacing:0.43px;}
#t1e_191{left:35px;bottom:256px;letter-spacing:-0.03px;word-spacing:0.63px;}
#t1f_191{left:390px;bottom:256px;}
#t1g_191{left:407px;bottom:256px;letter-spacing:0.24px;word-spacing:-0.06px;}
#t1h_191{left:462px;bottom:264px;letter-spacing:-0.01px;}
#t1i_191{left:485px;bottom:256px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1j_191{left:35px;bottom:233px;letter-spacing:0.02px;word-spacing:0.34px;}
#t1k_191{left:35px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1l_191{left:35px;bottom:187px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1m_191{left:35px;bottom:163px;letter-spacing:0.04px;word-spacing:0.28px;}
#t1n_191{left:35px;bottom:140px;letter-spacing:0.18px;word-spacing:-0.24px;}
#t1o_191{left:368px;bottom:140px;}
#t1p_191{left:384px;bottom:140px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1q_191{left:35px;bottom:117px;letter-spacing:0.17px;word-spacing:-0.23px;}
#t1r_191{left:35px;bottom:94px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1s_191{left:35px;bottom:71px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1t_191{left:618px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1u_191{left:618px;bottom:754px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1v_191{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:0.31px;}
#t1w_191{left:618px;bottom:707px;letter-spacing:0.03px;word-spacing:1.38px;}
#t1x_191{left:618px;bottom:667px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1y_191{left:618px;bottom:645px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1z_191{left:618px;bottom:622px;letter-spacing:0.1px;word-spacing:0.26px;}
#t20_191{left:618px;bottom:599px;letter-spacing:0.1px;word-spacing:0.09px;}
#t21_191{left:618px;bottom:575px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t22_191{left:816px;bottom:575px;}
#t23_191{left:832px;bottom:575px;letter-spacing:0.16px;word-spacing:0.02px;}
#t24_191{left:618px;bottom:552px;letter-spacing:0.16px;word-spacing:0.02px;}
#t25_191{left:1018px;bottom:552px;}
#t26_191{left:1034px;bottom:552px;letter-spacing:0.26px;word-spacing:-0.07px;}
#t27_191{left:618px;bottom:529px;letter-spacing:0.4px;}
#t28_191{left:649px;bottom:536px;letter-spacing:-0.01px;}
#t29_191{left:672px;bottom:529px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2a_191{left:618px;bottom:506px;letter-spacing:0.05px;word-spacing:-0.12px;}
#t2b_191{left:926px;bottom:506px;letter-spacing:0.13px;word-spacing:-0.12px;}
#t2c_191{left:618px;bottom:482px;letter-spacing:0.28px;}
#t2d_191{left:662px;bottom:482px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2e_191{left:1086px;bottom:482px;letter-spacing:0.34px;}
#t2f_191{left:1142px;bottom:490px;letter-spacing:-0.01px;}
#t2g_191{left:618px;bottom:459px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2h_191{left:618px;bottom:436px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2i_191{left:842px;bottom:436px;}
#t2j_191{left:852px;bottom:436px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2k_191{left:1155px;bottom:436px;}
#t2l_191{left:618px;bottom:413px;letter-spacing:0.15px;word-spacing:-0.58px;}
#t2m_191{left:618px;bottom:390px;letter-spacing:-0.22px;}
#t2n_191{left:659px;bottom:390px;letter-spacing:0.43px;word-spacing:-1.48px;}
#t2o_191{left:687px;bottom:390px;letter-spacing:0.11px;word-spacing:-0.54px;}
#t2p_191{left:618px;bottom:366px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2q_191{left:618px;bottom:343px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2r_191{left:618px;bottom:320px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2s_191{left:618px;bottom:297px;letter-spacing:0.15px;word-spacing:-0.08px;}
#t2t_191{left:618px;bottom:273px;letter-spacing:0.05px;word-spacing:0.16px;}
#t2u_191{left:618px;bottom:250px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2v_191{left:618px;bottom:227px;letter-spacing:0.06px;word-spacing:0.14px;}
#t2w_191{left:618px;bottom:187px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2x_191{left:618px;bottom:163px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2y_191{left:618px;bottom:140px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2z_191{left:618px;bottom:117px;letter-spacing:0.08px;word-spacing:0.41px;}
#t30_191{left:920px;bottom:117px;letter-spacing:0.1px;word-spacing:0.08px;}
#t31_191{left:618px;bottom:94px;letter-spacing:0.16px;word-spacing:0.23px;}
#t32_191{left:618px;bottom:71px;letter-spacing:0.14px;word-spacing:-0.22px;}
#t33_191{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_191{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_191{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_191{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_191{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_191{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_191{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_191{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_191{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s8_191{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts191" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg191Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg191" style="-webkit-user-select: none;"><object width="1210" height="935" data="191/191.svg" type="image/svg+xml" id="pdf191" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_191" class="t s0_191">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_191" class="t s1_191">© </span>
<span id="t3_191" class="t s0_191">(NCCN </span>
<span id="t4_191" class="t s1_191">© </span>
<span id="t5_191" class="t s0_191">), All rights reserved. NCCN Guidelines </span>
<span id="t6_191" class="t s1_191">® </span>
<span id="t7_191" class="t s0_191">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_191" class="t s2_191">NCCN Guidelines Version 4.2024 </span>
<span id="t9_191" class="t s2_191">Head and Neck Cancers </span>
<span id="ta_191" class="t s3_191">MS-50 </span>
<span id="tb_191" class="t s4_191">malnutrition). Locoregional treatment (eg, surgery, RT, ablative therapies) </span>
<span id="tc_191" class="t s4_191">may be used for oligometastatic disease. </span>
<span id="td_191" class="t s5_191">628-630 </span>
<span id="te_191" class="t s4_191">Historically, single-agent and combination systemic therapy have both </span>
<span id="tf_191" class="t s4_191">been used. </span>
<span id="tg_191" class="t s5_191">547 </span>
<span id="th_191" class="t s4_191">Response rates to single-agent therapies range from 15% to </span>
<span id="ti_191" class="t s4_191">35%. </span>
<span id="tj_191" class="t s5_191">548,631,632 </span>
<span id="tk_191" class="t s4_191">Randomized trials assessing a cisplatin-based combination </span>
<span id="tl_191" class="t s4_191">regimen (cisplatin/5-FU) versus single-agent therapy with cisplatin, 5-FU, </span>
<span id="tm_191" class="t s4_191">or methotrexate showed significantly higher response rates, but no </span>
<span id="tn_191" class="t s4_191">difference in OS and greater toxicity for the combination </span>
<span id="to_191" class="t s4_191">regimen. </span>
<span id="tp_191" class="t s5_191">537,538,541,633,634 </span>
<span id="tq_191" class="t s4_191">Complete response is associated with longer </span>
<span id="tr_191" class="t s4_191">survival and, although infrequent, has been reported more often with </span>
<span id="ts_191" class="t s4_191">combination regimens. </span>
<span id="tt_191" class="t s5_191">538 </span>
<span id="tu_191" class="t s4_191">A phase III randomized trial (EXTREME) of 442 </span>
<span id="tv_191" class="t s4_191">patients found that cetuximab plus cisplatin/5-FU or carboplatin/5-FU </span>
<span id="tw_191" class="t s4_191">improved response rate (36% vs. 20%; </span><span id="tx_191" class="t s6_191">P </span><span id="ty_191" class="t s4_191">&lt; .001) and median survival </span>
<span id="tz_191" class="t s4_191">compared to the standard chemotherapy doublet of platinum/5-FU in a </span>
<span id="t10_191" class="t s4_191">patient population predominantly linked to tobacco and alcohol use (10.1 </span>
<span id="t11_191" class="t s4_191">vs. 7.4 months; </span><span id="t12_191" class="t s6_191">P </span><span id="t13_191" class="t s4_191">= .04). </span>
<span id="t14_191" class="t s5_191">635 </span>
<span id="t15_191" class="t s4_191">A randomized phase III trial found no </span>
<span id="t16_191" class="t s4_191">significant difference in survival when comparing cisplatin/5-FU and </span>
<span id="t17_191" class="t s4_191">cisplatin/paclitaxel. </span>
<span id="t18_191" class="t s5_191">537 </span>
<span id="t19_191" class="t s4_191">Trials evaluating immune checkpoint inhibitors demonstrated efficacy in </span>
<span id="t1a_191" class="t s4_191">patients with recurrent or metastatic SCCHN. </span>
<span id="t1b_191" class="t s5_191">636-638 </span>
<span id="t1c_191" class="t s4_191">Pembrolizumab, an </span>
<span id="t1d_191" class="t s4_191">anti-PD-1 antibody, was evaluated as a first-line option for recurrent or </span>
<span id="t1e_191" class="t s4_191">metastatic SCCHN in the KEYNOTE-048 trial (</span><span id="t1f_191" class="t s6_191">N </span><span id="t1g_191" class="t s4_191">= 882). </span>
<span id="t1h_191" class="t s5_191">636 </span>
<span id="t1i_191" class="t s4_191">Patients were </span>
<span id="t1j_191" class="t s4_191">randomized to receive pembrolizumab, pembrolizumab with a platinum </span>
<span id="t1k_191" class="t s4_191">and 5-FU, or the EXTREME regimen. In the total population, an OS </span>
<span id="t1l_191" class="t s4_191">benefit was observed in the pembrolizumab/platinum/5-FU arm, </span>
<span id="t1m_191" class="t s4_191">compared to the EXTREME arm (median OS 13 vs. 10.7 months, </span>
<span id="t1n_191" class="t s4_191">respectively; HR, 0.77; 95% CI, 0.63–0.93; </span><span id="t1o_191" class="t s6_191">P </span><span id="t1p_191" class="t s4_191">= .003). PFS, however, did </span>
<span id="t1q_191" class="t s4_191">not significantly differ between these two study arms. Median duration of </span>
<span id="t1r_191" class="t s4_191">response was greater in patients treated with pembrolizumab </span>
<span id="t1s_191" class="t s4_191">monotherapy or pembrolizumab with chemotherapy, compared to </span>
<span id="t1t_191" class="t s4_191">patients treated with the EXTREME regimen. It should be noted that </span>
<span id="t1u_191" class="t s4_191">Grade 3–5 toxicity was observed in 85% of patients receiving </span>
<span id="t1v_191" class="t s4_191">pembrolizumab/platinum/5-FU, and in 55% of patients receiving </span>
<span id="t1w_191" class="t s4_191">pembrolizumab monotherapy. </span>
<span id="t1x_191" class="t s4_191">Results from KEYNOTE-048 showed that, in patients with a PD-L1 CPS </span>
<span id="t1y_191" class="t s7_191">of ≥20 or ≥1, median OS was better in patients who received </span>
<span id="t1z_191" class="t s4_191">pembrolizumab monotherapy, compared to those who received the </span>
<span id="t20_191" class="t s4_191">EXTREME regimen (median 14.9 vs. 10.7 months, respectively; HR, </span>
<span id="t21_191" class="t s4_191">0.61; 95% CI, 0.45–0.83; </span><span id="t22_191" class="t s6_191">P </span><span id="t23_191" class="t s7_191">&lt; .001, for CPS ≥20; median 12.3 vs. 10.3 </span>
<span id="t24_191" class="t s4_191">months, respectively; HR, 0.78; 95% CI, 0.64–0.96; </span><span id="t25_191" class="t s6_191">P </span><span id="t26_191" class="t s4_191">= .009, for CPS </span>
<span id="t27_191" class="t s7_191">≥1). </span>
<span id="t28_191" class="t s5_191">636 </span>
<span id="t29_191" class="t s4_191">In an update with a median study follow-up of 45.0 months, OS </span>
<span id="t2a_191" class="t s4_191">improved with pembrolizumab in the PD-</span><span id="t2b_191" class="t s7_191">L1 CPS ≥ 20 (HR, 0.61; 95% CI, </span>
<span id="t2c_191" class="t s4_191">0.46–</span><span id="t2d_191" class="t s7_191">0.81) and CPS ≥ 1 populations (HR, 0.74; 95% CI, 0.61</span><span id="t2e_191" class="t s4_191">–0.89). </span>
<span id="t2f_191" class="t s5_191">639 </span>
<span id="t2g_191" class="t s4_191">OS improved with pembrolizumab and chemotherapy in the PD-L1 CPS </span>
<span id="t2h_191" class="t s7_191">≥ 20 (HR, 0.62; 95% CI, 0.46</span><span id="t2i_191" class="t s4_191">–</span><span id="t2j_191" class="t s7_191">0.84), CPS ≥ 1 (HR, 0.64; 95% CI, 0.53</span><span id="t2k_191" class="t s4_191">– </span>
<span id="t2l_191" class="t s4_191">0.78), and total (HR, 0.71; 95% CI, 0.59–0.85) populations. This supports </span>
<span id="t2m_191" class="t s4_191">CPS </span><span id="t2n_191" class="t s7_191">≥ 1 </span><span id="t2o_191" class="t s4_191">for pembrolizumab monotherapy, and no PD-L1-based selection </span>
<span id="t2p_191" class="t s4_191">for combination of chemotherapy and pembrolizumab. No formal </span>
<span id="t2q_191" class="t s4_191">comparison exists between both pembrolizumab-containing arms, and </span>
<span id="t2r_191" class="t s4_191">the selection of regimens remains based on clinical judgement. The one </span>
<span id="t2s_191" class="t s4_191">difference observed was that the PFS of subsequent therapy was similar </span>
<span id="t2t_191" class="t s4_191">after pembrolizumab and longer after pembrolizumab and taxane- </span>
<span id="t2u_191" class="t s4_191">containing chemotherapy and shorter after pembrolizumab and similar </span>
<span id="t2v_191" class="t s4_191">after pembrolizumab and non-taxane–containing chemotherapy. </span>
<span id="t2w_191" class="t s4_191">The panel considers immunotherapy as the preferred first-line systemic </span>
<span id="t2x_191" class="t s4_191">therapy option for all patients with recurrent, unresectable, or metastatic </span>
<span id="t2y_191" class="t s4_191">disease who have no surgical or radiotherapeutic option. Specifically, </span>
<span id="t2z_191" class="t s4_191">pembrolizumab alone (for patients with </span><span id="t30_191" class="t s7_191">CPS ≥1) or </span>
<span id="t31_191" class="t s4_191">pembrolizumab/platinum/5-FU are both category 1 preferred first-line </span>
<span id="t32_191" class="t s4_191">options based on the results of KEYNOTE-048; the combination regimen </span>
<span id="t33_191" class="t s8_191">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
